-
公开(公告)号：WO2010027236A3
公开(公告)日：2010-06-17
申请号：PCT/KR2009005073
申请日：2009-09-08
Applicant: LG LIFE SCIENCES LTD , LEE CHANG SEOK , LEE TAE HEE , YOON SOOK KYUNG , CHOI JEUNG SOON , JANG YONG JIN , KIM SUNG WOOK , CHANG HYE KYUNG , PARK MI JEONG , KIM TAE HUN , AHN YOUNG HA , PARK HEE DONG , PARK HYUN JUNG , LIM DONG CHUL , LEE JOO YOUN , LEE SUNG HACK , PARK WAN SU , OH YEONG SOO
Inventor： LEE CHANG SEOK , LEE TAE HEE , YOON SOOK KYUNG , CHOI JEUNG SOON , JANG YONG JIN , KIM SUNG WOOK , CHANG HYE KYUNG , PARK MI JEONG , KIM TAE HUN , AHN YOUNG HA , PARK HEE DONG , PARK HYUN JUNG , LIM DONG CHUL , LEE JOO YOUN , LEE SUNG HACK , PARK WAN SU , OH YEONG SOO
IPC: C07D495/04
CPC classification number: C07D495/04 , C07D519/00
Abstract: The present invention relates to a fused heterocyclic compound having the Formula 1, which is useful as a platelet aggregation inhibitor, a method for preparing the same, and a pharmaceutical composition for inhibiting platelet aggregation comprising the same.
Abstract translation: 本发明涉及用作血小板聚集抑制剂的具有式1的稠合杂环化合物，其制备方法和包含其的血小板聚集抑制药物组合物。
-
公开(公告)号：WO2010005257A3
公开(公告)日：2010-04-01
申请号：PCT/KR2009003783
申请日：2009-07-10
Applicant: LG LIFE SCIENCES LTD , CHUNG YOUNG SIK , KIM YUN SIK , LIM CHANG BAEG , LEE SUNG HACK , KANG HYUN SU , CHUNG SOO YONG
Inventor： CHUNG YOUNG SIK , KIM YUN SIK , LIM CHANG BAEG , LEE SUNG HACK , KANG HYUN SU , CHUNG SOO YONG
CPC classification number: A61K9/00
Abstract: The present invention relates to a drug delivery system for oral administration of a new, controlled-release drug for angina treatment, and more specifically to a sustained-release pharmaceutical preparation containing Nicorandil that uses a polysaccharide, fatty acid ester, and optionally an alkalinizing agent so that it is bioavailable in vivo and also exhibits a release pattern wherein Nicorandil can be continuously released from the preparation over 12 to 24 hours following administration.
Abstract translation: 本发明涉及口服给药用于心绞痛治疗的新型控释药物的给药系统，并且更具体地涉及含有尼可地尔的缓释药物制剂，其使用多糖，脂肪酸酯和任选的碱化剂 因此它在体内是生物可利用的并且还表现出释放模式，其中尼可地尔可以在给药后12至24小时内从制剂中连续释放。
-
Patent Agency Ranking3.发明申请COMPLEX FORMULATION COMPRISING LERCANIDIPINE HYDROCHLORIDE AND VALSARTAN AND METHOD FOR THE PREPARATION THEREOF 审中-公开包含盐酸川芎嗪和缬沙坦的复合制剂及其制备方法
公开(公告)号：WO2012077968A3
公开(公告)日：2012-07-26
申请号：PCT/KR2011009413
申请日：2011-12-07
Applicant: LG LIFE SCIENCES LTD , CHUNG YOUNG SIK , PARK SOO AH , KIM REE SUN , KIM SUNG IL , JUHN JAE HYEON , KIM DONG KYU , KIM YOO RIN , PARK HEE DONG , PARK SEONG JAE , LEE SUNG HACK , KIM JU HYUN , JUNG MIN YOUNG
Inventor： CHUNG YOUNG SIK , PARK SOO AH , KIM REE SUN , KIM SUNG IL , JUHN JAE HYEON , KIM DONG KYU , KIM YOO RIN , PARK HEE DONG , PARK SEONG JAE , LEE SUNG HACK , KIM JU HYUN , JUNG MIN YOUNG
IPC: A61K31/4422 , A61K9/16 , A61K31/41 , A61P9/00
CPC classification number: A61K9/1635 , A61K9/1652 , A61K9/2027 , A61K9/2054 , A61K9/209 , A61K9/2095 , A61K9/5084 , A61K31/41 , A61K31/4422 , A61K2300/00
Abstract: The present invention relates to a pharmaceutical composition comprising lercanidipine hydrochloride and valsartan as active components and a method for the preparation thereof. The pharmaceutical composition comprising lercanidipine hydrochloride and valsartan according to the present invention has a superior effect on the prevention and treatment of cardiovascular diseases and their complex diseases, and reduces the adverse effects of each component. In addition, the present composition comprises lercanidipine hydrochloride and valsartan in a separated form so as to increase the dissolution rates of both components and reduce the adverse effects.
Abstract translation: 本发明涉及包含盐酸乐卡地平和缬沙坦作为活性成分的药物组合物及其制备方法。 本发明的包含盐酸乐卡地平和缬沙坦的药物组合物对心血管疾病及其复杂疾病的预防和治疗具有优越的效果，并且减少了各成分的不利影响。 另外，本发明组合物包含分离形式的乐卡地平盐酸盐和缬沙坦，以增加两种组分的溶解速率并减少不利影响。
-
4.发明申请COMPLEX FORMULATION COMPRISING LERCANIDIPINE HYDROCHLORIDE AND VALSARTAN AND METHOD FOR THE PREPARATION THEREOF 审中-公开包含LERCANIDIPINE HYDROCHLORIDE和VALSARTAN的复合配方及其制备方法
公开(公告)号：WO2012077968A2
公开(公告)日：2012-06-14
申请号：PCT/KR2011/009413
申请日：2011-12-07
Applicant: LG LIFE SCIENCES LTD. , CHUNG, Young Sik , PARK, Soo Ah , KIM, Ree Sun , KIM, Sung Il , JUHN, Jae Hyeon , KIM, Dong Kyu , KIM, Yoo Rin , PARK, Hee Dong , PARK, Seong Jae , LEE, Sung Hack , KIM, Ju Hyun , JUNG, Min Young
Inventor： CHUNG, Young Sik , PARK, Soo Ah , KIM, Ree Sun , KIM, Sung Il , JUHN, Jae Hyeon , KIM, Dong Kyu , KIM, Yoo Rin , PARK, Hee Dong , PARK, Seong Jae , LEE, Sung Hack , KIM, Ju Hyun , JUNG, Min Young
IPC: A61K31/4422 , A61K31/41 , A61K9/16 , A61P9/00
CPC classification number: A61K9/1635 , A61K9/1652 , A61K9/2027 , A61K9/2054 , A61K9/209 , A61K9/2095 , A61K9/5084 , A61K31/41 , A61K31/4422 , A61K2300/00
Abstract: The present invention relates to a pharmaceutical composition comprising lercanidipine hydrochloride and valsartan as active components and a method for the preparation thereof. The pharmaceutical composition comprising lercanidipine hydrochloride and valsartan according to the present invention has a superior effect on the prevention and treatment of cardiovascular diseases and their complex diseases, and reduces the adverse effects of each component. In addition, the present composition comprises lercanidipine hydrochloride and valsartan in a separated form so as to increase the dissolution rates of both components and reduce the adverse effects.
Abstract translation: 本发明涉及药物组合物及其制备方法，所述药物组合物包含氯卡地平和盐酸缬沙坦作为活性成分。 包含本发明的氯卡地平盐酸盐和缬沙坦的药物组合物对预防和治疗心血管疾病及其复杂疾病具有优异的作用，并降低各组分的不利影响。 此外，本发明的组合物包含分离形式的氯卡地平盐酸盐和缬沙坦，以增加两种组分的溶解速率并减少不利影响。
-
公开(公告)号：WO2010027236A2
公开(公告)日：2010-03-11
申请号：PCT/KR2009/005073
申请日：2009-09-08
Applicant: LG LIFE SCIENCES LTD. , LEE, Chang Seok , LEE, Tae Hee , YOON, Sook Kyung , CHOI, Jeung Soon , JANG, Yong Jin , KIM, Sung Wook , CHANG, Hye Kyung , PARK, Mi Jeong , KIM, Tae Hun , AHN, Young Ha , PARK, Hee Dong , PARK, Hyun Jung , LIM, Dong Chul , LEE, Joo Youn , LEE, Sung Hack , PARK, Wan Su , OH, Yeong Soo
Inventor： LEE, Chang Seok , LEE, Tae Hee , YOON, Sook Kyung , CHOI, Jeung Soon , JANG, Yong Jin , KIM, Sung Wook , CHANG, Hye Kyung , PARK, Mi Jeong , KIM, Tae Hun , AHN, Young Ha , PARK, Hee Dong , PARK, Hyun Jung , LIM, Dong Chul , LEE, Joo Youn , LEE, Sung Hack , PARK, Wan Su , OH, Yeong Soo
IPC: C07D495/04
CPC classification number: C07D495/04 , C07D519/00
Abstract: The present invention relates to a fused heterocyclic compound having the Formula 1, which is useful as a platelet aggregation inhibitor, a method for preparing the same, and a pharmaceutical composition for inhibiting platelet aggregation comprising the same.
Abstract translation: 本发明涉及具有式1的稠合杂环化合物，其可用作血小板聚集抑制剂，其制备方法和包含其的用于抑制血小板聚集的药物组合物。
-
6.发明申请DIPEPTIDYL PEPTIDASE-IV INHIBITING COMPOUNDS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS ACTIVE AGENT 审中-公开二肽基肽酶-IV抑制化合物，其制备方法以及含有该化合物作为活性剂的药物组合物
公开(公告)号：WO2009082134A3
公开(公告)日：2009-09-24
申请号：PCT/KR2008007543
申请日：2008-12-19
Applicant: LG LIFE SCIENCES LTD , LEE CHANG-SEOK , YIM HYEON JOO , KIM KYOUNG-HEE , LEE JAEICK , LEE SUNG-HACK , LEE KYU WOONG , LEE HEE BONG , PARK WAN SU , MIN CHANGHEE
Inventor： LEE CHANG-SEOK , YIM HYEON JOO , KIM KYOUNG-HEE , LEE JAEICK , LEE SUNG-HACK , LEE KYU WOONG , LEE HEE BONG , PARK WAN SU , MIN CHANGHEE
IPC: C07D471/04
CPC classification number: C07D471/04
Abstract: Disclosed herein are novel compounds of Formula (1) as defined in the specification having excellent inhibitory activity against dipeptidyl peptidase-IV (DPP-IV), methods of preparing the same and pharmaceutical compositions comprising the same as an active agent.
Abstract translation: 本文公开了如本说明书中所定义的具有优异的抗二肽基肽酶-IV（DPP-IV）抑制活性的式（1）化合物，其制备方法和包含其作为活性剂的药物组合物。
-
7.发明申请DIPEPTIDYL PEPTIDASE-IV INHIBITING COMPOUNDS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS ACTIVE AGENT 审中-公开DIPEPTIDYL PEPTIDASE-IV抑制化合物，其制备方法和含有它们作为活性代谢物的药物组合物
公开(公告)号：WO2009082134A2
公开(公告)日：2009-07-02
申请号：PCT/KR2008/007543
申请日：2008-12-19
Applicant: LG LIFE SCIENCES, LTD. , LEE, Chang-Seok , YIM, Hyeon Joo , KIM, Kyoung-Hee , LEE, Jaeick , LEE, Sung-Hack , LEE, Kyu Woong , LEE, Hee Bong , PARK, Wan Su , MIN, Changhee
Inventor： LEE, Chang-Seok , YIM, Hyeon Joo , KIM, Kyoung-Hee , LEE, Jaeick , LEE, Sung-Hack , LEE, Kyu Woong , LEE, Hee Bong , PARK, Wan Su , MIN, Changhee
IPC: C07D471/04
CPC classification number: C07D471/04
Abstract: Disclosed herein are novel compounds of Formula (1) as defined in the specification having excellent inhibitory activity against dipeptidyl peptidase-IV (DPP-IV), methods of preparing the same and pharmaceutical compositions comprising the same as an active agent.
Abstract translation: 本文公开的是具有对二肽基肽酶-IV（DPP-IV）具有优异抑制活性的本说明书中定义的新颖的式（1）化合物，其制备方法和包含其作为活性剂的药物组合物。
-
-
-
-
-
-
Search Results
7
records
(took 0.019 seconds)
